Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N2QW
|
|||
| Former ID |
DIB015717
|
|||
| Drug Name |
Patritumab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y] | Phase 1 | [1] | |
| Company |
Daiichi sankyo
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Erbb3 tyrosine kinase receptor (Erbb-3) | Target Info | . | [2] |
| KEGG Pathway | ErbB signaling pathway | |||
| Calcium signaling pathway | ||||
| Endocytosis | ||||
| Proteoglycans in cancer | ||||
| MicroRNAs in cancer | ||||
| NetPath Pathway | TNFalpha Signaling Pathway | |||
| Panther Pathway | Cadherin signaling pathway | |||
| EGF receptor signaling pathway | ||||
| Pathway Interaction Database | ErbB2/ErbB3 signaling events | |||
| ErbB receptor signaling network | ||||
| a6b1 and a6b4 Integrin signaling | ||||
| WikiPathways | ErbB Signaling Pathway | |||
| Apoptosis-related network due to altered Notch3 in ovarian cancer | ||||
| Signaling Pathways in Glioblastoma | ||||
| miR-targeted genes in muscle cell - TarBase | ||||
| Heart Development | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01957280) Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287). U.S. National Institutes of Health. | |||
| REF 2 | Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):511-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.